6月6日沪指上涨0.04%，盘后龙虎榜数据显示，机构现身26只个股龙虎榜，净买入16只，净卖出10只。 深沪股通席位出现在16只个股龙虎榜。 证券时报·数据宝统计显示，6月6日机构专用席位现身26只个股龙虎榜，合计净买入4.33亿元。个股来 看，净买入16只，净卖出10只。 机构龙虎榜净买卖个股 机构专用席位净买入金额最多的是雄帝科技，该股今日收盘下跌10.56%，全天换手率为47.82%，成交 额为17.48亿元。因日换手率达47.90%上榜龙虎榜，前五大买卖营业部中有4家机构专用席位，为买一、 买三、买四、卖三，合计净买入8184.08万元。资金流向方面，该股全天资金净流出1.19亿元。 6月6日机构龙虎榜净买卖个股 | 代码 | 简称 | 当日涨跌幅（%） | 当日换手率（%） | 机构净买入（万元） | | --- | --- | --- | --- | --- | | 300546 | 雄帝科技 | -10.56 | 47.82 | 8184.08 | | 000506 | 中润资源 | 9.99 | 9.67 | 6398.51 | | 300255 | 常山药业 | 15.12 | 7.54 | ...

Market Overview - On June 6, the Shanghai Composite Index rose by 0.04%, while the Shenzhen Component Index fell by 0.19%, and the ChiNext Index decreased by 0.45% [2] - A total of 54 stocks appeared on the daily trading list due to unusual trading activity, with the highest net inflow of funds into China Electric Power Xinlong (002298.SZ) amounting to 236 million yuan [2] Stock Performance - China Electric Power Xinlong saw a closing price increase of 9.96% with a turnover rate of 19.42%, while Snowman Co., Ltd. (002639.SZ) experienced a net outflow of 210 million yuan and closed down by 1.23% with a turnover rate of 46.27% [2] - Among the 54 stocks, 34 were net bought, and 20 were net sold, indicating a general preference for buying [2] Institutional Activity - On June 6, 26 stocks on the trading list had institutional participation, with a total net purchase of 439 million yuan, where institutions net bought 16 stocks and net sold 10 stocks [2] - The stock with the highest institutional net purchase was Xiongdi Technology (300546.SZ), which closed down by 10.56% with a turnover rate of 47.82% [3] Northbound Capital - Northbound capital participated in 16 stocks on the trading list, with a total net purchase of 304 million yuan, including a net purchase of 54.65 million yuan from the Shanghai Stock Connect and 249 million yuan from the Shenzhen Stock Connect [6] - The stock with the highest net purchase from northbound capital was Changshan Pharmaceutical (300255.SZ), amounting to 202 million yuan, while Snowman Co., Ltd. had the highest net sell of 107 million yuan [6] Common Trends - Both institutions and northbound capital collectively net bought stocks such as Changshan Pharmaceutical, Hailian Jinhui, Hengbao Co., Ltd., Haoshanghao, Maiwei Biotechnology, and Hunan Development [7] - There was a divergence in the trading of Cambridge Technology (603083.SH) and Zhongchong Co., Ltd., with institutions net buying Zhongchong Co., Ltd. while northbound capital net sold it [7]

Core Insights - The ESG investment funds are gaining significant attention in the financial market, with approximately 1200 funds and a total scale exceeding 820 billion yuan as of June 6 [3][4] - Various types of ESG funds are emerging, including pure ESG theme funds, ESG strategy funds, and environmental protection theme funds, reflecting a growing recognition of sustainable investment [3][4] Fund Performance - Among the ESG funds, 84 funds have achieved over 10% returns this year, with 20 funds exceeding 20% and 8 funds surpassing 50% [4][5] - Notable performers include the Bank of China Hong Kong Stock Connect Medical A/C with over 60% returns and the Huatai-PineBridge Health Living One-Year Holding A/C with over 55% returns [5] Market Trends - The increasing number of ESG funds indicates a rising investor interest in corporate social responsibility and sustainable development [4][7] - Fund companies are strategically positioning themselves to attract a broader client base, particularly younger generations and institutional investors who prefer investments aligned with their values [4][7] Regulatory Environment - Since 2020, there has been a growing emphasis on ESG regulations, with various policies being introduced to guide enterprises in ESG practices [7][8] - Central and local governments are actively promoting ESG development, with initiatives aimed at enhancing the quality of state-owned enterprises and fostering sustainable urban development [7][8]

Core Viewpoint - The A-share market experienced fluctuations with mixed performance among the three major indices, reflecting a volatile trading environment influenced by sector-specific trends and investor sentiment [1][2]. Market Performance - As of the market close, the Shanghai Composite Index rose by 0.04%, while the Shenzhen Component Index and the ChiNext Index fell by 0.19% and 0.45%, respectively. The total trading volume for the day was approximately 1.18 trillion yuan [2]. Sector Highlights - The metal, Tianjin Free Trade Zone, and communication services sectors showed notable gains, with specific stocks like Shengda Resources, Silver Industry, and Hunan Silver reaching their daily limit [4]. - The football concept stocks saw a resurgence, with Co-Creation Lawn achieving a "5 consecutive limit up" and Jinling Sports experiencing significant volatility, ultimately closing up by 8.92% after a sharp intraday drop [4][7]. Football Concept Stocks - The recent popularity of the "Su Super" (Jiangsu Province City Football League) has positively impacted the A-share football concept stocks, which have been on an upward trend, although some adjustments were noted [6][11]. - Co-Creation Lawn reported a 69.93% revenue contribution from leisure grass and 20.25% from sports grass in 2024, indicating a strong market position despite potential fluctuations due to external events [11]. Innovative Drug Sector - The innovative drug sector showed signs of recovery, with stocks like Changshan Pharmaceutical and Hai Chen Pharmaceutical hitting their daily limit, reflecting a growing interest in this area [12][13]. - Changshan Pharmaceutical's stock price increased by 15.12%, reaching a historical high, with a cumulative increase of 106.42% since May [13][16]. Company Announcements - Co-Creation Lawn confirmed that its business operations remain normal, with no significant changes in fundamentals, despite the heightened market attention [11]. - Jinling Sports acknowledged the abnormal volatility in its stock price, attributing it to market sentiment and potential irrational trading behaviors, indicating a need for caution [11]. Future Outlook - Analysts suggest that the recent surge in "Su Super" concept stocks is primarily driven by market sentiment rather than fundamental changes, highlighting the risk of a potential correction as enthusiasm wanes [11]. - The innovative drug sector is entering a technology-driven cycle, with a focus on antibody drugs and ADCs, suggesting a promising outlook for companies in this field [16].

Market Overview - The three major A-share indices showed mixed results, with the Shanghai Composite Index up by 0.04%, the Shenzhen Component down by 0.19%, and the ChiNext Index down by 0.45% [1] - The total market turnover was 11,772 billion, a decrease of 1,398 billion compared to the previous day [1] - Over 2,600 stocks in the market experienced gains [1] Sector Performance - The sectors that performed well included non-ferrous metals, civil explosives, agricultural chemical products, and Hainan Free Trade Zone, while sectors such as military equipment restructuring, beauty, and IP economy saw declines [1] - The non-ferrous metals sector led the gains, with stocks like Shengda Resources, Baiyin Nonferrous Metals, and Hunan Baiyin hitting the daily limit [1] - The agricultural chemical products sector was active, with stocks like Meibang Co., Sulihua Co., and Changqing Co. also reaching the daily limit [1] - Innovative drug concept stocks saw a rebound in the afternoon, with XinNuoWei and HaiChen Pharmaceutical hitting the daily limit, while Changshan Pharmaceutical reached a historical high [1] - Military equipment restructuring concept stocks weakened, with Hunan Tianyan dropping over 7% at the close [1] - New consumption sectors, including beauty care and pet economy, collectively adjusted, with stocks like Haoyue Care, Guangbo Co., and Zhongchong Co. leading the declines [1] Commodity Insights - The price of silver surged significantly, reaching over $36 per ounce for the first time since February 2012, driven by concerns over potential U.S. tariffs on key metals [13] - The price of the herbicide Acetochlor in China increased from 68,000 yuan per ton at the beginning of 2024 to 120,000 yuan per ton by May 25, 2025, marking a 76% increase [14] Notable Stocks - Co-Creation Lawn achieved a five-day limit increase [5] - Jinshi Technology and Filinger both achieved a four-day limit increase [6] - Zhongjia Bochuang, Zhongdian Xinlong, Yiming Pharmaceutical, and Huamai Technology achieved a three-day limit increase [7] - Zhongrun Resources, Xiamen Xinda, and Xinlian Electronics achieved a two-day limit increase [8] Emerging Trends - The "Belt and Road" initiative saw nine stocks hitting the daily limit, with six stocks achieving consecutive limit increases [9] - The "Western Development" sector had ten stocks hitting the daily limit, with four stocks achieving consecutive limit increases [12] - The "Data Center" sector also had nine stocks hitting the daily limit, with five stocks achieving consecutive limit increases [12]

创新药概念股反复活跃，新诺威（300765）尾盘20cm涨停，常山药业（300255）涨超16%创出历史新 高，迈威生物、赛伦生物涨超10%，海创药业、神州细胞跟涨。 ...

Summary of Key Points from the Conference Call Industry Overview - The conference focused on the innovative drug sector, particularly in oncology, highlighting advancements in treatments for non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and other malignancies [1][4][24]. Core Insights and Arguments - **Innovative Drug Performance**: - **Innovent Biologics IBI363**: In NSCLC, the objective response rate (ORR) for squamous cell carcinoma patients reached 43.3%, with a progression-free survival (PFS) of 7.3 months. For adenocarcinoma patients, ORR was 28% with a PFS of 4.2 months, indicating potential in immune-resistant patients [1][5][6]. - **Kanglongda SKP164**: Demonstrated strong data in EGFR-mutant NSCLC in both third-line and first-line treatments, with promising results in TNBC [1][4][7]. - **Zhongjin Tianqing**: The combination of PD-1 with chemotherapy and Anlotinib showed significant superiority over standard treatments in squamous cell carcinoma [1][4]. - **Baiyi Tianheng ADC**: Achieved an overall survival (OS) of 15 months and an ORR of 70%-80% in second-line NSCLC treatment [1][4]. - **3SBio 707**: A PD-1/LAG3 bispecific antibody that has shown promising early data in NSCLC and has entered a licensing agreement with Pfizer [1][4][8]. - **Emerging Competitors**: - **Zejing ZG006**: A DL3/CD3 triantibody showing superior ORR compared to Teclistamab, indicating strong potential in its category [1][4][8]. - **Zejing 005**: A PD-1/TIGIT bispecific antibody with promising early data in cervical cancer [1][4][8]. Additional Important Insights - **Clinical Data as a Key Factor**: High-quality and differentiated clinical data are essential for innovative drugs to demonstrate their unique value and competitiveness in the global market [2]. - **Potential Best-in-Class Candidates**: Several domestic innovative molecules are positioned to become best-in-class, including 3SBio 707 and Zejing's products, based on their clinical performance [8][24]. - **Focus on Unmet Medical Needs**: IBI363's efficacy in immune-resistant tumors like NSCLC, colorectal cancer, and melanoma highlights its potential in addressing significant unmet medical needs [9][10]. - **Regulatory and Market Dynamics**: The conference underscored the importance of regulatory approvals and market strategies for the successful commercialization of these innovative therapies [24]. Conclusion - The conference highlighted significant advancements in the innovative drug sector, particularly in oncology, with several products showing promising clinical data. The emphasis on high-quality clinical evidence and the potential for best-in-class candidates suggests a competitive landscape for future drug development and market entry.

证券代码：300765 证券简称：新诺威 公告编号：2025-053 关于使用部分闲置募集资金进行现金管理的进展公告 石药创新制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召开第 六届董事会第二十二次会议、第六届监事会第十七次会议，于 2025 年 4 月 15 日 召开 2024 年年度股东大会，会议审议并通过了《关于使用部分闲置募集资金及 自有资金进行现金管理的议案》。在不影响募集资金投资项目建设和公司正常经 营的情况下，公司及子公司使用不超过人民币 8.00 亿元（含本数）额度的闲置募 集资金及不超过人民币 8.00 亿元（含本数）的自有资金进行现金管理，投资安全 性高、流动性好的保本型产品（包括结构性存款、大额存单等），使用期限自股 东大会审议通过之日起 12 个月内有效。在上述额度及决议有效期内，业务可循 环滚动开展。具体内容详见巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于使用部分闲置募集资金及自有资金进行现金管理的公告》 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Fuqua Precision Medical Mixed A Fund, which has shown significant growth in recent months and year-to-date [1] - As of June 4, 2025, the latest net value of the fund is 3.1336 yuan, reflecting a growth of 1.37% [1] - The fund's one-month return is 9.95%, ranking 66 out of 2330 in its category, while its three-month return is 30.39%, ranking 10 out of 2320 [1] - Year-to-date, the fund has achieved a return of 40.63%, ranking 12 out of 2307 [1] Group 2 - The top ten stock holdings of the Fuqua Precision Medical Mixed A Fund account for a total of 69.71%, with significant positions in companies such as Baile Tianheng (9.66%), Haizike (9.65%), and Kelun Pharmaceutical (9.10%) [1] - The fund was established on November 16, 2017, and as of March 31, 2025, it has a total scale of 3.746 billion yuan [1] - The fund manager, Zhao Wei, has extensive experience in the pharmaceutical and investment sectors, having held various positions in companies such as GlaxoSmithKline and China Merchants Fund Management [2]

Core Viewpoint - In May 2025, over 70% of the 8,451 comparable mixed funds experienced net value increases, indicating a positive trend in the market [1] Fund Performance Summary - A total of 54 mixed funds achieved a monthly increase of over 10%, with Jinxin Value Selected Mixed A and C leading at 19.38% and 19.36% respectively [2] - Jinxin Value Selected Mixed A and C, established on September 1, 2017, reported year-to-date returns of 32.65% and 32.60%, and cumulative returns of 48.85% and 49.57% as of May 30, 2025 [2] - The top ten holdings of Jinxin Value Selected Mixed A and C focus on the pharmaceutical and biotechnology sectors, particularly in innovative industries [2] - Huabao Pharmaceutical and Biological Mixed A achieved a monthly increase of 11.49%, with a year-to-date return of 41.55% and a cumulative return of 381.22% since its inception [3] Fund Decline Summary - 15 mixed funds saw declines exceeding 10% in May, with Furong Fuxin Mixed C and A at the bottom with -12.39% and -12.38% respectively [4] - Furong Fuxin Mixed C and A focus on humanoid robotics, with their top holdings including Huachen Equipment and Qinchuan Machine Tool [4] Fund Manager Insights - The current fund manager for Jinxin Value Selected Mixed A and C is Zhao Haoran, who has a background in financial research and joined Jinxin Fund in August 2022 [2] - Huabao Pharmaceutical and Biological Mixed A is managed by Zhang Jintao, who has extensive experience in investment research across various financial institutions [3] - Furong Fuxin Mixed C and A are co-managed by Li Yanzheng and Mao Yunhong, both of whom have significant experience in research and fund management [4]